Russia: Patent Office relies on report from Academy of Sciences
Managing IP is part of the Delinian Group, Delinian Limited, 4 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Russia: Patent Office relies on report from Academy of Sciences

After filing a patent application, 18 months elapse before the application is published. After receiving a request for substance examination, the patent office starts the examination procedure. There may be cases where the application concerns questionable scientific substantiation of technical results on which the claimed invention is based.

This was the case in a patent application for "A Method of Treatment and Prophylaxis of Complications in Diabetic Patients". The patent application was examined and the grant of a patent was refused by the examiner. The applicant appealed the decision of the patent office to the Chamber of Patent Disputes. The chamber noted that the technical result according to the invention was improving efficiency of treatment and prophylaxis of complications in diabetic patients. According to the documents on file, improvement of treatment and prophylaxis concerned Type 2 diabetes.

It should be noted that the claimed technical result (improvement of efficiency of treatment) presupposes comparison of results of a method with the closest prior art. Efficiency of treatment is characterised by important criteria, such as convalescence, longevity, quality of life, frequency of complications and other factors.

This leads to the conclusion that it is possible to judge about efficiency of treatment only on the basis of comparison with authentic groups of patients which should be present in documents on the application file.

The Chamber of Patent Disputes examined the documents on file and the appeal and found that the applicant produced data obtained in experiments on rats with experimental alloxan and streptozotocin diabetes to support the attained technical result. The rats took water treated according to the invention and another control group drank ordinary non-treated water. No sugar reducing therapy was used in both cases, as a result of which data was obtained showing that in the case of alloxan diabetes there was no substantial reduction in glucose level while in the case of streptozotocin, the glucose level did not change at all. The level of glycolized haemoglobin became lower in both cases.

The obtained results on lowering glycolized haemoglobin in rats cannot be directly used for patients suffering from Type 2 diabetes because alloxan and streptozotocin diabetes are models of a different pathology, i.e. Type 1 diabetes develops for different reasons from Type 2 diabetes.

During examination of the patent application, the patent office sent an enquiry to the Russian Academy of Sciences seeking to clarify whether realisation of biological effects of mineral water treated by a specific method was possible according to the method disclosed in the patent application.

The Academy of Sciences studied the issue and produced a report on the technical solution according to the controversial application.

It was pointed out in the report that it is recognised by the world of science that water does not have long-term memory of past mechanical, magnetic and electromagnetic influence or substances dissolved in it. There is no basis whatsoever to conclude that a molecular matrix exists in water which could serve as a long-term memory of influence on water. The mechanisms of realisation of biological effects of the treated mineral water remain unclear and are not supported by the results of experimental and clinical tests. The patent application concerning efficiency of treatment and prophylaxis of complications of diabetic patients is based on the unsubstantiated effect of enhanced biological activity of water with a degree of mineralisation 0.5 – 0.8 g/l. treated by electromagnetic radiation and a constant magnetic field. The claimed result does not comply with Russian and foreign investigation results concerning mechanisms of development of Type 1 and Type 2 diabetes which would clarify fundamentals of the disease and causes of development of vascular complications. Besides, the documents on file have no convincing evidence that the treated mineral water is effective when it is included in complex therapy in the case of diabetes.

Hence the expert commission of the academy confirmed the result of the patent examination which stated that the claimed effect is not achieved.

biriulin.jpg

Vladimir Biriulin


Gorodissky & PartnersRussia 129010, MoscowB. Spasskaya Str25, stroenie 3Tel: +7 495 937 6116 / 6109Fax: +7 495 937 6104 / 6123pat@gorodissky.ru www.gorodissky.com

more from across site and ros bottom lb

More from across our site

A 36-member team from Zhong Lun Law Firm, including six partners, will join the newly formed East IP Group
The Delhi High Court sided with Ericsson against Indian smartphone maker Lava, bringing the companies' nine-year dispute to a close
We provide a rundown of Managing IP’s news and analysis from the week, and review what’s been happening elsewhere in IP
Tennessee has passed the ELVIS Act, a law that fights against AI models that mimic the voice and likeness of music artists
Rob Stien, chief communications and public policy officer at InterDigital, says the EU has forgotten innovators while trying to solve an issue that doesn’t exist
As Australia’s Qantm IP leans towards being acquired by a private equity company, sources discuss what it could mean for IP firms
Law firms that are conscious of their role in society are more likely to win work, according to a survey of over 23,000 in-house professionals
Nghiem Xuan Bac Pham, managing partner of Vision & Associates, discusses opportunities created by the US-China rift as well as profitability issues facing IP practices
Douglas Leite and two of his colleagues were intrigued by Bhering Advogados’s mission to grow its patent litigation practice
Each week Managing IP speaks to a different IP practitioner about their life and career
Gift this article